Ni Sun-Suslow1, Emily W Paolillo1,2, Erin E Morgan1, Scott Letendre1,3, Jennifer Iudicello1, David J Moore1. 1. Department of Psychiatry, University of California San Diego, San Diego, CA. 2. San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA; and. 3. Department of Medicine, University of California San Diego, San Diego, CA.
Abstract
BACKGROUND: Frailty disproportionally affects people with HIV (PWH) and increased frailty in this already vulnerable population is associated with worse neurocognitive functioning. Whether frailty interacts with current and modifiable markers of HIV disease severity to synergistically increase risk for HIV-associated neurocognitive disorders (HAND), however, is unknown and important for informing the clinical care of aging PWH. SETTING: UC San Diego's HIV Neurobehavioral Research Program. METHODS: Participants were 178 PWH evaluated between 2014 and 2019. HIV disease severity was measured by current CD4 count and plasma HIV RNA. HAND diagnoses were made according to the Frascati criteria using a 7-domain neuropsychological battery, and the Fried phenotype criteria were used to assess frailty syndrome (0-5 symptoms). The independent and interactive effects of frailty and current HIV disease severity (ie, CD4 count and plasma HIV RNA) on HAND were examined using multiple logistic regressions. RESULTS: There was an interaction between CD4 count and frailty on HAND. Simple slopes showed that CD4 count and the likelihood of HAND were negatively associated at >1.25 symptoms of frailty, and conversely, frailty and HAND were negatively associated at 642 or less cells/mm. There were no significant independent or interactive effects of plasma HIV RNA and frailty on the likelihood of HAND. CONCLUSIONS: In addition to monitoring CD4 count, assessing for frailty may be critical in older adults with HIV to potentially mitigate poor neurobehavioral outcomes. Longitudinal follow-up studies are needed to determine the directionality of these findings.
BACKGROUND: Frailty disproportionally affects people with HIV (PWH) and increased frailty in this already vulnerable population is associated with worse neurocognitive functioning. Whether frailty interacts with current and modifiable markers of HIV disease severity to synergistically increase risk for HIV-associated neurocognitive disorders (HAND), however, is unknown and important for informing the clinical care of aging PWH. SETTING: UC San Diego's HIV Neurobehavioral Research Program. METHODS: Participants were 178 PWH evaluated between 2014 and 2019. HIV disease severity was measured by current CD4 count and plasma HIV RNA. HAND diagnoses were made according to the Frascati criteria using a 7-domain neuropsychological battery, and the Fried phenotype criteria were used to assess frailty syndrome (0-5 symptoms). The independent and interactive effects of frailty and current HIV disease severity (ie, CD4 count and plasma HIV RNA) on HAND were examined using multiple logistic regressions. RESULTS: There was an interaction between CD4 count and frailty on HAND. Simple slopes showed that CD4 count and the likelihood of HAND were negatively associated at >1.25 symptoms of frailty, and conversely, frailty and HAND were negatively associated at 642 or less cells/mm. There were no significant independent or interactive effects of plasma HIV RNA and frailty on the likelihood of HAND. CONCLUSIONS: In addition to monitoring CD4 count, assessing for frailty may be critical in older adults with HIV to potentially mitigate poor neurobehavioral outcomes. Longitudinal follow-up studies are needed to determine the directionality of these findings.
Authors: Kristine M Erlandson; Jennifer A Schrack; Catherine M Jankowski; Todd T Brown; Thomas B Campbell Journal: Curr HIV/AIDS Rep Date: 2014-09 Impact factor: 5.071
Authors: Loic Desquilbet; Lisa P Jacobson; Linda P Fried; John P Phair; Beth D Jamieson; Marcy Holloway; Joseph B Margolick Journal: J Gerontol A Biol Sci Med Sci Date: 2007-11 Impact factor: 6.053
Authors: Alan T Rodriguez-Penney; Jennifer E Iudicello; Patricia K Riggs; Katie Doyle; Ronald J Ellis; Scott L Letendre; Igor Grant; Steven Paul Woods Journal: AIDS Patient Care STDS Date: 2013-01 Impact factor: 5.078
Authors: Lindsay M K Wallace; Olga Theou; Judith Godin; Melissa K Andrew; David A Bennett; Kenneth Rockwood Journal: Lancet Neurol Date: 2019-02 Impact factor: 44.182
Authors: Stephanie Shiau; Alexis A Bender; Jane A O'Halloran; Erin Sundermann; Juhi Aggarwal; Keri N Althoff; Jason V Baker; Steven Deeks; Linda P Fried; Stephen Karpiak; Maile Y Karris; Thomas D Marcotte; Jean B Nachega; Joseph B Margolick; Kristine M Erlandson; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2020-09-23 Impact factor: 2.205
Authors: Mary Clare Masters; Jeremiah Perez; Kunling Wu; Ronald J Ellis; Karl Goodkin; Susan L Koletar; Adriana Andrade; Jingyan Yang; Todd T Brown; Frank J Palella; Ned Sacktor; Katherine Tassiopoulos; Kristine M Erlandson Journal: Clin Infect Dis Date: 2021-08-16 Impact factor: 20.999